In January of 2017, Charleston Laboratories announced the formation of Õlas Pharma, Inc., a wholly owned US subsidiary established to conduct commercialization activities for Charleston Laboratories’ pipeline of products. Product commercialization will address significant patient needs such as Opioid-Induced Nausea and Vomiting (OINV) and Migraine-Associated Nausea and Vomiting (MANV).
“The creation of a formal commercial presence has always been a part of Charleston Laboratories’ growth strategy and it is extremely gratifying to reflect on the hard work and successes that have made this a reality,” said Mr. Paul Bosse, President and Chief Executive Officer at Charleston Laboratories.
“The formation of Õlas Pharma lays the groundwork for our direct involvement in commercialization of our robust pipeline of drug candidates.”
Charleston Laboratories is a privately held, specialty pharmaceutical company focused on the research, development, and commercialization of novel pain products to prevent the burdensome side effects associated with drugs and conditions dominating the acute pain management markets.